Bioequivalance study of Famotidine 40 mg

Bioequivalance study of Famotidine 40 mg tablets manufactured by Iran daru pharmaceutical company on 24 healthy volunteers and comparing pharmacokinetics results with famotidine tablets manufactured by Ratiopharm.

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200513047423N9

Enrollment

Registered

2022-04-16

Start date

2022-06-10

Completion date

Unknown

Last updated

2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subject: Bioequivalence of Famotidine 40 mg Tablet and Comparison of Pharmacokinetic Parameters with Ratiopham Reference Tablet.

Interventions

Intervention 1: Intervention group1: One Famotidine 40 mg tablet manufactured by Iran Daru company (Test drug) is administrated to each of 12 healthy volunteer of group 1. Intervention 2: Interventio

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Healthy liver Healthy kidney Volunteers should not be too fat or too thin and their weight index should be in the appropriate range

Exclusion criteria

Exclusion criteria: Out of age ranges smoking pragnancy

Design outcomes

Primary

Measure	Time frame
Plasma concentration changing after administration of Famotidine tablet.Plasma concentration of famotidine at Tmax reaches about 200 ng/mL and its measurement range is from 10ng / mL to 700ng / mL. Timepoint: Initial blood sampling is performed before drug administration to obtain blank plasma chromatogram of each volunteers. Hence the Tmax of Famotidine is between 1 and 3 hours, so it is needed to have 5 blood sampling before Tmax. This period of time is called absorption phase. In the elimination phase (after Tmax) blood sampling carry out each hours. Method of measurement: In this study, the variable is plasma concentration of famotidine. High performance liquid chromatography is used to determine the concentration of famotidine in plasma.	—

Measure

Time frame

Plasma concentration changing after administration of Famotidine tablet.Plasma concentration of famotidine at Tmax reaches about 200 ng/mL and its measurement range is from 10ng / mL to 700ng / mL. Timepoint: Initial blood sampling is performed before drug administration to obtain blank plasma chromatogram of each volunteers. Hence the Tmax of Famotidine is between 1 and 3 hours, so it is needed to have 5 blood sampling before Tmax. This period of time is called absorption phase. In the elimination phase (after Tmax) blood sampling carry out each hours. Method of measurement: In this study, the variable is plasma concentration of famotidine. High performance liquid chromatography is used to determine the concentration of famotidine in plasma.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Amir mehdizahed

Ofoqh pharmed labratory

A_mehdizadeh@gmail.com+98 21 6673 8727

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026